arrow
J

Jean-Christophe Ianotto

CHU de Brest
H指数:29
被引数:4,363

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Allele burden expansion in JAK2V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment

JAK2<sup>V617F</sup>和CALR突变骨髓增殖性肿瘤中的等位基因负荷扩增预测疾病进展并与安归那治疗相关

2026-09-010
OAAI
Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis

非侵入性多参数表征原发性血小板增多症、骨髓纤维化前期和显性骨髓纤维化

Leukemia
IF13.4
2026-08-030
OA
Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?

费城染色体阴性骨髓增殖性肿瘤与获得性冯维勒布兰德综合征:仅在诊断时相关?

2026-07-010
PRE
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial

法国慢性期慢性髓性白血病患者中尼洛替尼与尼洛替尼联合聚乙二醇干扰素α-2a作为一线治疗的最终结果(PETALs):一项开放标签、多中心、随机III期试验

2026-04-300
PRE
Impact of Atrial Fibrillation on Thrombotic Complications in Myeloproliferative Neoplasms Real-World Analysis

心房颤动对骨髓增殖性肿瘤患者血栓并发症的影响:真实世界分析

2026-01-010
PRE
Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms

血栓性炎症与 Newly Diagnosed Myeloproliferative Neoplasms 患者的高血栓风险相关。

Leukemia
IF13.4
2025-12-230
PRE
Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms

鲁索利替尼和羟基脲是真实世界研究中骨髓增殖性肿瘤患者减轻水诱性瘙痒强度的最有效药物。

2025-12-010
OAAI
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study

共存骨髓增殖性肿瘤和淋巴性肿瘤:一项欧洲多中心回顾性研究

2025-10-170
OAAI
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study

加速期和原始细胞期骨髓增殖性肿瘤患者在接受单药或联合阿扎胞苷治疗且不符合强化疗或异基因造血细胞移植条件时的预后情况——一项FIM研究

2025-09-040
PREAI
A molecular signature predicts hematologic evolution in polycythemia vera patients

分子特征可预测原发性红细胞增多症患者的血液学演变

Leukemia
IF13.4
2025-06-180
OAAI
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera

治疗对青少年和年轻成人真性红细胞增多症和原发性血小板增多症的影响

LEUKEMIA
IF13.4
2025-03-120
OA
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM
2024-02-250
OAAI
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloproliferatifs
2024-02-084
OAAI
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification
LEUKEMIA
IF13.4
2023-12-278
PRE